Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carmen T. Navia"'
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Specificity profiling is a requirement for monoclonal antibodies (mAbs) and antibody-directed biotherapeutics such as CAR-T cells prior to initiating human trials. However, traditional approaches to assess the specificity of mAbs, primarily tissue cr
Externí odkaz:
https://doaj.org/article/e71bd051d23e4748a5db97586af61d16
Autor:
Yimei Li, John M. Maris, Swetha Raman, Jean-Philippe Julien, Bruce R. Pawel, Maria Lane, Dimiter S. Dimitrov, Kristen A. Upton, Kristopher R. Bosse, Daniel B. Harmon, Carmen T. Navia, Doncho V. Zhelev, Hong Cui, Khushbu Patel, Samantha Buongervino, Yanping Wang, Komal S. Rathi, Zhongyu Zhu, Daniel Martinez, Benjamin Martinez
Publikováno v:
Cell Reports Medicine
Summary Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2’s immunotherapeutic attributes by finding that it is also a highly expre
Autor:
Khushbu Patel, Hong Cui, Kristen A. Upton, Kristopher R. Bosse, Carmen T. Navia, Doncho V. Zhelev, Daniel Martinez, Daniel B. Harmon, Jean-Philippe Julien, John M. Maris, Benjamin Martinez, Bruce R. Pawel, Swetha Raman, Yanping Wang, Maria Lane, Dimiter S. Dimitrov, Samantha Buongervino, Komal S. Rathi, Zhongyu Zhu
Publikováno v:
SSRN Electronic Journal.
The signaling co-receptor heparan sulfate proteoglycan GPC2 is a MYCN-activated, differentially-expressed cell surface oncoprotein and candidate immunotherapeutic target in neuroblastoma. Here we build on GPC2’s attributes as a robust target for im